Neuroscientific Biopharmaceuticals Ltd (ASX: NSB) Share Price and News
Price
$0.035
Movement
0.00 (0.0)
as at 11 Apr - Closed (20 mins delayed)
52 Week Range
$0.033 - $0.062
1 Year Return
-44.44%
Neuroscientific Biopharmaceuticals Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$5.06 million
P/E Ratio
4.27
Dividend Yield
0.00%
Shares Outstanding
144.60 million
Earnings per share
0.008
Dividend per share
N/A
Year To Date Return
6.06%
Earnings Yield
23.43%
Franking
-
Share Price
$0.035
Day Change
0.00 (0.0)
52 Week Range
$0.033 - $0.062
Yesterday's Close
$0.035
Today's Open
$0.035
Days Range
$0.035 - $0.035
Volume
31,468
Avg. Volume (1 month)
74,446
Turnover
$1,101
as at 11 Apr - Closed
Neuroscientific Biopharmaceuticals Ltd (ASX: NSB)
Latest News
Healthcare Shares
Here are the 5 best performing ASX biotech shares of 2021
Healthcare Shares
Neuroscientific Biopharmaceuticals (ASX:NSB) share price surges 11% on drug update
Share Gainers
These 3 ASX Healthcare shares have soared over 10% today
Share Gainers
Neuroscientific Biopharmaceuticals (ASX:NSB) share price leaps 11% on study update
Share Market News
Neuroscientific Biopharmaceuticals (ASX:NSB) share price jumps 9% before trading halt
Healthcare Shares
NeuroScientific Biopharmaceuticals (ASX:NSB) share price wobbles on study results
Share Market News
This ASX biotech share is up 20% today
Share Market News
Why this ASX microcap skyrocketed 190% on Tuesday
NSB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| 26th Feb 2025 2025-02-26T17:27:11 | Half Yearly Report and Accounts | YesNo | 5:27pm | 22 | 3.7M |
| 30th Jan 2025 2025-01-30T09:11:12 | Quarterly Activities/Appendix 4C Cash Flow Report | YesNo | 9:11am | 8 | 1.4M |
| 24th Jan 2025 2025-01-24T11:33:53 | Change of Registered Office Address | YesNo | 11:33am | 1 | 521k |
| 22nd Jan 2025 2025-01-22T16:30:11 | Notification of cessation of securities - NSB | YesNo | 4:30pm | 4 | 13k |
| 6th Nov 2024 2024-11-06T14:36:22 | Results of Annual General Meeting | YesNo | 2:36pm | 2 | 475k |
| 29th Oct 2024 2024-10-29T09:32:31 | Quarterly Activities/Appendix 4C Cash Flow Report | YesNo | 9:32am | 8 | 1.4M |
| 2nd Oct 2024 2024-10-02T15:54:09 | Letter to Shareholders and Proxy Form | YesNo | 3:54pm | 3 | 508k |
| 2nd Oct 2024 2024-10-02T15:53:04 | Notice of Annual General Meeting | YesNo | 3:53pm | 19 | 441k |
| 29th Aug 2024 2024-08-29T19:21:43 | Appendix 4G & Corporate Governance Statement | YesNo | 7:21pm | 29 | 781k |
| 29th Aug 2024 2024-08-29T19:21:08 | 2024 Annual Report & Appendix 4E | YesNo | 7:21pm | 65 | 6.7M |
About Neuroscientific Biopharmaceuticals Ltd
Neuroscientific Biopharmaceuticals Ltd is an Australian-based biotechnology company. The company is engaged in the development of diagnostic and therapeutic treatments for neurodegenerative diseases through preclinical studies of patented technologies.
NSB Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 11 Apr 2025 | $0.04 | $0.00 | 0.00% | 31,468 | $0.04 | $0.04 | $0.04 |
| 10 Apr 2025 | $0.04 | $0.00 | 0.00% | 9,500 | $0.04 | $0.04 | $0.04 |
| 08 Apr 2025 | $0.03 | $0.00 | 0.00% | 9,523 | $0.04 | $0.04 | $0.03 |
| 07 Apr 2025 | $0.04 | $0.00 | 0.00% | 305,219 | $0.04 | $0.04 | $0.04 |
| 04 Apr 2025 | $0.04 | $0.00 | 0.00% | 45,613 | $0.04 | $0.04 | $0.04 |
| 03 Apr 2025 | $0.04 | $0.00 | 0.00% | 242,334 | $0.04 | $0.04 | $0.04 |
| 02 Apr 2025 | $0.04 | $0.00 | 0.00% | 52,346 | $0.04 | $0.04 | $0.04 |
| 01 Apr 2025 | $0.04 | $0.00 | 0.00% | 58,342 | $0.04 | $0.04 | $0.04 |
| 27 Mar 2025 | $0.04 | $0.00 | 0.00% | 69,999 | $0.04 | $0.04 | $0.04 |
| 26 Mar 2025 | $0.04 | $0.00 | 0.00% | 21,874 | $0.04 | $0.04 | $0.04 |
| 25 Mar 2025 | $0.04 | $0.00 | 0.00% | 58,357 | $0.04 | $0.04 | $0.04 |
| 24 Mar 2025 | $0.04 | $0.00 | 0.00% | 76,734 | $0.04 | $0.04 | $0.04 |
| 21 Mar 2025 | $0.04 | $0.00 | 0.00% | 32,574 | $0.04 | $0.04 | $0.04 |
| 20 Mar 2025 | $0.04 | $0.00 | 0.00% | 41,569 | $0.04 | $0.04 | $0.04 |
| 19 Mar 2025 | $0.04 | $0.00 | 0.00% | 15,600 | $0.04 | $0.04 | $0.04 |
| 18 Mar 2025 | $0.04 | $0.00 | 0.00% | 94,500 | $0.04 | $0.04 | $0.04 |
| 17 Mar 2025 | $0.04 | $0.00 | 0.00% | 133 | $0.04 | $0.04 | $0.04 |
| 14 Mar 2025 | $0.04 | $0.00 | 0.00% | 125,000 | $0.04 | $0.04 | $0.04 |
| 13 Mar 2025 | $0.04 | $0.00 | 0.00% | 105,516 | $0.04 | $0.04 | $0.04 |
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Anton Uvarov | Non-Executive Director | Nov 2022 |
Dr Uvarov has experience as an equity analyst in the healthcare industry with a focus on the biotechnology sector, both domestically and internationally.
|
| Mr Christopher Ntoumenopoulos | Non-Executive DirectorNon-Executive Chairman | Nov 2023 |
Mr Ntoumenopoulos is the Managing Director at Twenty 1 Corporate, an Australian-based corporate advisory firm. Mr Ntoumenopoulos has experience in financial markets, with over 20 years of raising capital and providing corporate advisory services.
|
| Dr Anthony (Tony) Keating | Executive Director | Dec 2023 |
Dr Keating is an experienced entrepreneur and CEO, having co-founded and led ResApp Health Ltd from start-up to its ultimate acquisition by Pfizer for $180 million.
|
| Mr Clarke Barlow | Non-Executive Director | Nov 2023 |
Mr Barlow is a Financial Adviser and Capital Markets Specialist with over 20 years of experience in the Financial Services Industry in Australia and the United Kingdom. Mr Barlow has experience providing corporate advisory services for companies listed on the ASX across a variety of industries, with a particular focus on growth opportunities in the biotechnology, technology, industrial and resources industries.
|
| Dr Linda Friedland | Non-Executive Director | Oct 2023 |
Dr Friedland with over 25 years of experience in clinical medicine and an international advisor to many Fortune and Forbes global companies. She consults with healthcare, biotech, corporate, and financial insitutions. Linda is a non-executive director on several Healthcare boards within Australia and abroad. Among her roles, Dr Friedland is Deputy Chairman of the Neurological Council of Western Australia (NCWA), senior consultant to TargImmune Therapeutics (Basel, Switzerland), co-founder and director of FFD Capital LLC (USA) and Asia- Pacific partner for Camelot BioCapital. An author of seven healthcare-related bestsellers with a career in television and health media, she has developed public health and disease management programs in Asia, USA, Australia, Africa, and the UK and delivered keynote addresses in more than 30 countries
|
| Mr Christopher (Chris) Bryan Achurch | Company Secretary | Feb 2024 |
-
|
| Christopher (Chris) Bryan Achurch | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| MCRAE Technology Pty Ltd | 19,122,262 | 13.22% |
| BNP Paribas Noms Pty Ltd <Drp> | 17,780,425 | 12.30% |
| MCRAE Investments Pty Ltd | 4,985,659 | 3.45% |
| Utas Holdings Pty Ltd | 3,954,123 | 2.73% |
| Citicorp Nominees Pty Limited | 3,393,062 | 2.35% |
| Lehav Pty Ltd <The Vhl Family A/C> | 2,872,644 | 1.99% |
| ECU Holdings Pty Ltd | 2,555,556 | 1.77% |
| HSBC Custody Nominees (Australia) Limited | 2,107,712 | 1.46% |
| Mr Edward Joseph & Mrs Margaret Mary Gettingby | 2,090,000 | 1.45% |
| Ms Yulia Uvarova | 2,000,000 | 1.38% |
| Whale Watch Holdings Limited | 1,927,341 | 1.33% |
| Mr Mohammed Akbar Asem | 1,770,183 | 1.22% |
| Mr Edward Joseph & Mrs Margaret Mary Gettingby i | 1,703,333 | 1.18% |
| Solequest Pty Ltd | 1,601,422 | 1.11% |
| Dossman Pty Ltd | 1,595,666 | 1.10% |
| Ice Lake Investments Pty Ltd | 1,550,000 | 1.07% |
| Trevor Borrows Investment Pty Ltd | 1,500,000 | 1.04% |
| Aukera Capital Pty Ltd <Aukera Discretionary A/C> | 1,200,000 | 0.83% |
| BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> | 1,153,551 | 0.80% |
| Mr Paul John Rennie | 1,090,753 | 0.75% |